Clinical Trial

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

Study acronym: LGS
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2012-05-22; most recent amendment 2021-02-17.
Trial Details
NCT Number NCT01604395
Lead Sponsor LG Chem
Conditions Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age, Idiopathic Short Stature
Enrollment 6,000 participants
Start Date 2012-01
Primary Completion 2032-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-02-21